Allergy Drops vs Shots: An Honest, Evidence-Based Comparison

The most rigorous head-to-head comparison — Nelson et al. 2015 in the Journal of Allergy and Clinical Immunology: In Practice — found no statistically significant difference between sublingual and subcutaneous immunotherapy for grass pollen, with a symptom-score standardized mean difference of just 0.01. However, indirect analyses disagree: Di Bona et al. (2012) found larger effect sizes for shots, though with substantial heterogeneity. Where shots have the stronger evidence base is for cat dander, mold, and tree pollen, where multi-allergen drop data are thinner. Direct head-to-head randomized trials have been small and underpowered to detect the modest differences that may exist. For grass and dust mite, the modalities appear broadly comparable.

Sublingual drops carry a lower risk of severe systemic reactions than shots. A 2024 meta-analysis (Janz et al., 26 studies, 7,827 patients) found local oral or gastrointestinal reactions in about 40.8% of drop users, and no SLIT fatalities have been reported worldwide. In our program fewer than 0.1% of patients have systemic reactions. By contrast, AAAAI surveillance attributes roughly one fatality per 2.5 million injections to shots, with a systemic reaction rate near 0.1% per injection. This is why sublingual products can be dosed at home after an initial supervised dose. Drops are not risk-free, however — eosinophilic esophagitis and uncontrolled asthma are contraindications, and epinephrine is prescribed.

Both modalities need at least three years of treatment to produce durable post-treatment benefit. The GRASS trial (Scadding et al., JAMA 2017) showed that two-year courses of either sublingual or subcutaneous immunotherapy failed to produce lasting benefit after stopping. After three-year courses, both show sustained relief for at least two to three additional years. Durham et al. (1999, New England Journal of Medicine) demonstrated that three to four years of shots produced persistent remission across multiple follow-up seasons, and grass tablet trials confirmed disease modification two years after stopping. Long-term data beyond three years post-treatment are currently stronger for shots than for drops, but both appear to offer years of benefit after a complete course.

Allergy shots can treat virtually any IgE-mediated inhalant allergen — grasses, trees, weeds, dust mites, cat, dog, mold, and stinging-insect venoms — using customized multi-allergen vials. FDA-approved sublingual tablets each cover only one allergen, which is impractical for the roughly 60% of allergic patients sensitized to multiple triggers. Compounded multi-allergen sublingual drops can address several allergens at once and are used off-label, but they lack the standardized phase-3 evidence base of FDA-approved tablets, and potency can vary between compounding sources. Your specific sensitization profile, confirmed by allergy testing, determines which modality fits best for the allergens actually driving your symptoms.

Real-world adherence is poor for both, and most patients do not complete a full course. The landmark Kiel et al. 2013 study in the Journal of Allergy and Clinical Immunology, analyzing 6,486 Dutch patients, found shots had a higher three-year completion rate (23%) than drops (7%). The likely explanation is that clinic-supervised injections enforce attendance, while daily at-home dosing depends on the patient remembering and staying motivated without visible short-term progress. The most cited reason drop users quit is perceived lack of efficacy. Importantly, treatment choice alone does not determine adherence — telehealth monitoring, education, and structured follow-up meaningfully improve completion rates for both modalities.

Coverage differs sharply by modality. Commercial insurance covers in-office allergy shots at virtually all major payers, and Medicare Part B covers shots at 80%. FDA-approved sublingual tablets usually require prior authorization but are covered by most commercial plans. Compounded multi-allergen sublingual drops, however, are used off-label and are generally not covered by any insurer, including Medicare and Medicaid, so patients typically pay out of pocket. Drops are HSA- and FSA-eligible, which can offset the cost with pre-tax dollars. This coverage asymmetry — shots covered, liquid drops generally not — is an important practical consideration when weighing the two options.